Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Initial clinical characteristics of all SS patients included in this review, the 47 patients whose treatment was described and the 30 patients treated with corticosteroids

From: Treatment of Satoyoshi syndrome: a systematic review

  All patients N = 64 Patients where treatment was specified N = 47 Patients treated with corticosteroids N = 30
Age of onset 13.02 ± 9.08 14.19 ± 10.35 13.80 ± 10.32
Female sex 47/64 (73%) 35/47 (74%) 23/30 (77%)
Muscle manifestations 100% 100% 100%
Alopecia 100% 100% 100%
Alopecia universalis 40/64 (63%) 25/47 (53%) 17/30 (57%)
Diarrhea 37/64 (58%) 26/47 (55%) 17/30 (57%)
Weight loss, low weight or growth retardation 33/64 (52%) 23/47 (49%) 14/30 (47%)
Skeletal alterations 22/64 (34%) 16/47 (34%) 10/30 (33%)
Amenorrhea 23/47 (49%) 15/35 (43%) 9/23 (39%)
ANA + 17/64 (27%) 17/47 (36%) 13/30 (43%)
Other autoantibodies 15/64 (23%) 15/47 (32%) 11/30 (37%)
Deaths 7 (11%) 2 (4%) 0 (0%)